538 related articles for article (PubMed ID: 29768210)
1. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.
Avanzi MP; Yeku O; Li X; Wijewarnasuriya DP; van Leeuwen DG; Cheung K; Park H; Purdon TJ; Daniyan AF; Spitzer MH; Brentjens RJ
Cell Rep; 2018 May; 23(7):2130-2141. PubMed ID: 29768210
[TBL] [Abstract][Full Text] [Related]
2. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.
Yeku OO; Purdon TJ; Koneru M; Spriggs D; Brentjens RJ
Sci Rep; 2017 Sep; 7(1):10541. PubMed ID: 28874817
[TBL] [Abstract][Full Text] [Related]
3. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
5. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
[TBL] [Abstract][Full Text] [Related]
6. IL-18R-dependent and independent pathways account for IL-18-enhanced antitumor ability of CAR-T cells.
Huang Y; Li D; Zhang PF; Liu M; Liang X; Yang X; Jiang L; Zhang LF; Zhou WL; Su JH; Gong YL; Gou HF; Wei YQ; Wang W
FASEB J; 2020 Jan; 34(1):1768-1782. PubMed ID: 31914650
[TBL] [Abstract][Full Text] [Related]
7. Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.
Li X; Daniyan AF; Lopez AV; Purdon TJ; Brentjens RJ
Leukemia; 2021 Feb; 35(2):506-521. PubMed ID: 32447345
[TBL] [Abstract][Full Text] [Related]
8. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
Zhu Y; Wang K; Yue L; Zuo D; Sheng J; Lan S; Zhao Z; Dong S; Hu S; Chen X; Feng M
Pharmacol Res; 2024 May; 203():107186. PubMed ID: 38641176
[TBL] [Abstract][Full Text] [Related]
10. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
[TBL] [Abstract][Full Text] [Related]
11. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
Soltantoyeh T; Akbari B; Shahosseini Z; Mirzaei HR; Hadjati J
Front Immunol; 2024; 15():1362904. PubMed ID: 38855110
[TBL] [Abstract][Full Text] [Related]
14. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors
Koneru M; Purdon TJ; Spriggs D; Koneru S; Brentjens RJ
Oncoimmunology; 2015 Mar; 4(3):e994446. PubMed ID: 25949921
[TBL] [Abstract][Full Text] [Related]
15. Versatile strategy for controlling the specificity and activity of engineered T cells.
Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
[TBL] [Abstract][Full Text] [Related]
16. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting.
Lee EHJ; Murad JP; Christian L; Gibson J; Yamaguchi Y; Cullen C; Gumber D; Park AK; Young C; Monroy I; Yang J; Stern LA; Adkins LN; Dhapola G; Gittins B; Chang WC; Martinez C; Woo Y; Cristea M; Rodriguez-Rodriguez L; Ishihara J; Lee JK; Forman SJ; Wang LD; Priceman SJ
Nat Commun; 2023 Aug; 14(1):4737. PubMed ID: 37550294
[TBL] [Abstract][Full Text] [Related]
17. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors.
Li S; Xia Y; Hou R; Wang X; Zhao X; Guan Z; Ma W; Xu Y; Zhang W; Liu D; Zheng J; Shi M
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167159. PubMed ID: 38583815
[TBL] [Abstract][Full Text] [Related]
18. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
19. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
20. Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells.
Yoshikawa T; Ito Y; Wu Z; Kasuya H; Nakashima T; Okamoto S; Amaishi Y; Zhang H; Li Y; Matsukawa T; Inoue S; Kagoya Y
Cell Rep Med; 2024 May; 5(5):101526. PubMed ID: 38670095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]